---
reference_id: "PMID:40855169"
title: Digital twins for noninvasively measuring predictive markers of right heart failure.
authors:
- Geddes JR
- Jensen CW
- Tanade C
- Ghorbannia A
- Fudim M
- Patel MR
- Randles A
journal: NPJ Digit Med
year: '2025'
doi: 10.1038/s41746-025-01920-8
content_type: abstract_only
---

# Digital twins for noninvasively measuring predictive markers of right heart failure.
**Authors:** Geddes JR, Jensen CW, Tanade C, Ghorbannia A, Fudim M, Patel MR, Randles A
**Journal:** NPJ Digit Med (2025)
**DOI:** [10.1038/s41746-025-01920-8](https://doi.org/10.1038/s41746-025-01920-8)

## Content

1. NPJ Digit Med. 2025 Aug 25;8(1):545. doi: 10.1038/s41746-025-01920-8.

Digital twins for noninvasively measuring predictive markers of right heart 
failure.

Geddes JR(1), Jensen CW(1)(2), Tanade C(1), Ghorbannia A(1), Fudim M(3)(4), 
Patel MR(3)(4), Randles A(5).

Author information:
(1)Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
(2)Division of Cardiovascular & Thoracic Surgery, Department of Surgery, Duke 
University, Durham, NC 27708, USA.
(3)Division of Cardiology, Department of Medicine, Duke University, Durham, NC 
27708, USA.
(4)Duke Clinical Research Institute, Durham, NC 27708, USA.
(5)Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA. 
amanda.randles@duke.edu.

Digital twins offer a promising approach to advancing healthcare by providing 
precise, noninvasive monitoring and early detection of diseases. In heart 
failure (HF), a leading cause of mortality worldwide, they can improve patient 
monitoring and clinical outcomes by simulating hemodynamic changes indicative of 
worsening HF. Current techniques are limited by their invasiveness and lack of 
scalability. We present a novel framework for HF digital twins that predicts 
patient-specific hemodynamic metrics in the pulmonary arteries using 3D 
computational fluid dynamics to address these limitations. We introduce a 
strategy to determine the minimal geometric complexity required for accurate 
pressure prediction and explore the effects of varying boundary conditions. By 
validating our digital twins against invasively-measured data, we demonstrate 
their potential to improve HF management by enabling continuous, noninvasive 
monitoring and early identification of worsening HF. This proof-of-concept study 
lays the groundwork for integrating digital twin technology into personalized HF 
care.

Â© 2025. The Author(s).

DOI: 10.1038/s41746-025-01920-8
PMCID: PMC12379216
PMID: 40855169

Conflict of interest statement: Competing interests: Dr Fudim was supported by 
Alleviant, Gradient, Reprieve, Sardocor, and Doris Duke. He is a consultant/has 
ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, 
Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, Broadview, 
Cadence, Cardiosense, Cardioflow, CVRx, Daxor, Edwards LifeSciences, Echosens, 
EKO, Endotronix, Feldschuh Foundation, Fire1, FutureCardia, Galvani, Gradient, 
Hatteras, HemodynamiQ, Impulse Dynamics, Medtronic, Merck, NovoNordisk, 
NucleusRx, NXT Biomedical, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, 
Procyreon, Proton Intelligence, Puzzle, ReCor, SCPharma, Shifamed, Splendo, STAT 
Health, Summacor, SyMap, Terumo, Vascular Dynamics, Vironix, Viscardia, Zoll. 
Dr. Patel has been supported with research grants from Bayer, Janssen, 
Heartflow, Novartis, and the NIH. He serves on the advisory board or as a 
consultant for Bayer, Janssen, Novartis.